Interview with Pierre Boyer, Servier Czech Republic
You joined this affiliate in October of 2011, having spent the preceding three years as GM for Servier Slovakia. What are the principal differences you found between these two markets?…
Address: SERVIER s.r.o., Praha City Center, Klimentská 46, 110 02, Prague,Czech Republic
Tel: +420 222 118 111
Servier started its activities in the Czech Republic in October of 1994. Throughout its years on the Czech pharmaceutical market, the company has built a strong position in the field of cardiology, diabetology, internal medicine, psychiatry and angiology. Servier’s drugs have been used by more than 800,000 Czech patients.
In 1998, Servier CZ established a research center for clinical development, based in Prague. The aim of the center is to organize clinical trials in accordance with Good Clinical Practice (GCP) and local laws.
In 2012, Servier ranked among the top five major pharmaceutical companies in the Czech Republic. The company has long been one of the most dynamic organizations in the Czech pharmaceutical market.
Innovative pharmaceutical products in the fields of cardiology, diabetology, internal medicine, psychiatry and angiology.
You joined this affiliate in October of 2011, having spent the preceding three years as GM for Servier Slovakia. What are the principal differences you found between these two markets?…
Teva Czech Republic & Slovakia GM Juan Carlos Conde describes how the Czech Republic hosts Teva’s third largest manufacturing site within Europe and the recent implementation of a more efficient…
Vojtěch Mészáros, Executive Director of Egis Praha, speaks about his background in the industry, his drive to promote biosimilar products, and how the company maneuvers around the growing price pressures…
Janssen Czech Republic’s MD reviews his longstanding career within the company and highlights how founder Dr. Paul Janssen’s legacy still influences operations today. He also compares the Czech regulatory environment…
The AIFP’s Jakub Dvořáček explains the recently launched tool for information disclosure between pharmaceutical companies and doctors, highlighting the significance it holds for industry and country. Furthermore, he reviews the…
The chairman of the committee on health and social policy of the Czech Senate names the role that health insurance companies inherit and the transparency of the healthcare system as…
The ’90s was an enthusiastic time. With the fall of communism in 1989 and the emergence of the free economy, the international pharmaceutical industry arrived in the Czech Republic…
Ms. Hrdličková, can you please begin by introducing yourself to our readers, and providing a brief overview of your pharmaceutical career? My educational background is in general and molecular biology,…
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Dr. Sommermeyer, you’ve spent approximately two decades working for pharmaceutical companies throughout Europe. From a personal standpoint, why did you decide to leave the industry and found a consultancy? I…
Mr. Tichopad, can you please begin by introducing yourself and your company to our readers? My background is in bio-statistics. I am a biologist by education, and in the beginning…
Mr. Kužela, you have a very interesting background: from 1993 until 2011, you variously worked for the Staropramen beer factory and its parent organization, StarBev. You identify yourself as an…
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
See our Cookie Privacy Policy Here
